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Malignant melanomas are highly resistant to chemotherapy. First-line chemotherapeutics used in melanoma therapy are the
methylating agents dacarbazine (DTIC) and temozolomide (TMZ) and the chloroethylating agents BCNU and fotemustine. Here, we
determined the mode of cell death in 11 melanoma cell lines upon exposure to TMZ and fotemustine. We show for the first time
that TMZ induces apoptosis in melanoma cells, using therapeutic doses. For both TMZ and fotemustine apoptosis is the dominant
mode of cell death. The contribution of necrosis to total cell death varied between 10 and 40%. The O
6-methylguanine-DNA
methyltransferase (MGMT) activity in the cell lines was between 0 and 1100fmolmg
 1 protein, and there was a correlation between
MGMT activity and the level of resistance to TMZ and fotemustine. MGMT inactivation by O
6-benzylguanine sensitized all melanoma
cell lines expressing MGMT to TMZ and fotemustine-induced apoptosis, and MGMT transfection attenuated the apoptotic response.
This supports that O
6-alkylguanines are critical lesions involved in the initiation of programmed melanoma cell death. One of the cell
lines (MZ7), derived from a patient subjected to DTIC therapy, exhibited a high level of resistance to TMZ without expressing
MGMT. This was related to an impaired expression of MSH2 and MSH6. The cells were not cross-resistant to fotemustine. Although
these data indicate that methylating drug resistance of melanoma cells can be acquired by down-regulation of mismatch repair, a
correlation between MSH2 and MSH6 expression in the different lines and TMZ sensitivity was not found. Apoptosis in melanoma
cells induced by TMZ and fotemustine was accompanied by double-strand break (DSB) formation (as determined by H2AX
phosphorylation) and caspase-3 and -7 activation as well as PARP cleavage. For TMZ, DSBs correlated significantly with the apoptotic
response, whereas for fotemustine a correlation was not found. Melanoma lines expressing p53 wild-type were more resistant to
TMZ and fotemustine than p53 mutant melanoma lines, which is in marked contrast to previous data reported for glioma cells
treated with TMZ. Overall, the findings are in line with the model that in melanoma cells TMZ-induced O
6-methylguanine triggers the
apoptotic (and necrotic) pathway through DSBs, whereas for chloroethylating agents apoptosis is triggered in a more complex
manner.
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Melanoma is among the top six cancers responsible for cancer-
related mortality worldwide (Balch et al, 2001). Once melanoma
metastasises treatment outcome is poor. Only a few chemother-
apeutic agents have been shown to be active in the treatment of
melanomas. The most often used drug is dacarbazine (DTIC),
which needs metabolic activation to generate the active DNA-
methylating carbenium ions inside the cell (Hill, 1975). Temozo-
lomide (TMZ), which is a triazene derivative that needs no
metabolic activation, also has activity in melanoma cells. It
hydrolyses spontaneously in aqueous solution, giving rise to the
active metabolite 5-(3,3-methyltriazen-1-yl)imidazole-4-carboxa-
mide that further decomposes to yield DNA-methylating species
(Newlands et al, 1997). The response rate after treatment with
these methylating drugs is B20% (Newlands et al, 1992; Bleehen
et al, 1995; Middleton et al, 2000). Temozolomide penetrates well
the blood–brain barrier and, therefore, it is also used for the
treatment of brain metastases of melanomas (Bael et al, 2008). It
can be administered orally and is well tolerated.
An important mechanism of resistance to methylating agents is
DNA repair mediated by the damage-reversal suicide enzyme O
6-
methylguanine-DNA methyltransferase (MGMT). It repairs the
pre-toxic DNA lesion O
6-methylguanine (O
6MeG) by transfer of
the methyl group from guanine to an own cysteine residue (Pegg,
2000). This causes, in an expression-dependent manner, resistance
to methylating agents that produce O
6MeG (Kaina et al, 1991).
Similar to malignant gliomas, melanomas express, compared to
other cancers, quite low levels of MGMT (Chen et al, 1992; Kaina
et al, 2007), which might explain why melanomas respond to the
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smethylating drugs DTIC and TMZ, but not to many other
anticancer drugs. In view of the role of MGMT in the defence
against O
6MeG one might anticipate that MGMT determines the
clinical outcome in melanoma therapy with methylating drugs.
However, conflicting data have been reported. Thus, the pretreat-
ment levels of MGMT in biopsies of cutaneous tumours were not
related to the outcome (Middleton et al, 1998) whereas a later
study showed that MGMT expression in melanoma metastases was
related to the clinical response of the patients to DTIC-based
therapy (Ma et al, 2002a, 2003). Conversely, MGMT promoter
methylation was not clearly related to the patients response upon
TMZ treatment, although methylation threshold levels were also
discussed to have an impact on therapy (Rietschel et al, 2008). It
appears that melanoma cells are intrinsically resistant and acquire
drug resistance by different strategies (Soengas and Lowe, 2003) in
which MGMT is only one of several players.
The O
6-methylguanine-DNA methyltransferase also causes
resistance to chloroethylating agents like BCNU and the nitrosour-
ea analogue, fotemustine (for review see Kaina et al, 2007). These
agents are used in the therapy of metastatic melanoma either as a
single agent (Li and McClay, 2002) or in combination with
methylating agents, notably TMZ (Tas et al, 2007). Therapy with
fotemustine has response rates of B20%; only partial responses
were observed with a median of several months. The poor outcome
of metastatic melanomas to chemotherapy stresses the need for
improved strategies. A prerequisite for this would be the detailed
knowledge of how these drugs exert their cell killing effects in
malignant melanoma cells.
Temozolomide methylates DNA forming, among other lesions,
O
6MeG. The mechanism of apoptotic cell death triggered by
O
6MeG has been studied extensively in different cell systems,
including rodent cells (Tominaga et al, 1997; Meikrantz et al, 1998;
Ochs and Kaina, 2000; Roos et al, 2007b), human lymphocytes
(Dunkern et al, 2003; Hickman and Samson, 2004; Roos et al,
2004), and malignant glioma cells (Roos et al, 2007a). It has
become clear that O
6MeG mispaired with thymine is the critical
secondary pre-apoptotic DNA lesion. It has been proposed
that the processing of O
6MeG/T mismatches by MutSa-dependent
DNA mismatch repair (MMR) gives rise to activation of ATR-Chk1
signalling (Caporali et al, 2004; Stojic et al, 2004) and DNA
double-strand breaks (DSBs) that act as the ultimate trigger of the
apoptotic pathway (Ochs and Kaina, 2000; Roos and Kaina,
2006). Alternatively, MutSa/MutLa bound to O
6MeG/T lesions may
directly activate apoptotic signalling. Apart from the finding
that ATR/ATRIP is activated in the presence of MutSa-bound
O
6MeG/T mismatches (Yoshioka et al, 2006), evidence for this
model is scarce. Contrary to TMZ, fotemustine modifies
DNA by chloroethylation, giving rise to O
6-chloroethylguanine.
This lesion undergoes spontaneous inter- and intra-molecular
rearrangement to form a N1-guanine-N3-cytosine interstrand
crosslink (ICL; Tong et al, 1982). Although several other adducts
are also formed, these ICLs are believed to be responsible
for the killing effect of chloroethylating agents. Because MGMT
repairs O
6-chloroethylguanine before the ICL can form, and
O
6MeG before the mismatch can form, the repair protein is
considered as a key mechanism of resistance of tumour cells
against fotemustine, TMZ, and other anticancer drugs with similar
properties.
Although methylating and chloroethylating drugs are crucial in
primary therapy of metastatic melanomas, it is not known how
they exert killing effects in melanoma cells. In a recent study it was
reported that TMZ does not induce apoptosis, but senescence in
human melanoma cells (Mhaidat et al, 2007), which is surprising
in view of the fact that other cell systems such as malignant
gliomas undergo apoptosis very efficiently in response to TMZ
(Roos et al, 2007a). For fotemustine, it has been shown that
melanoma cells are killed by apoptosis (Passagne et al, 2003; Kissel
et al, 2006), but detailed studies on the mode of cell death by this
drug in melanoma cells are not available. Also, there is no
systematic study (utilising the same cell model) for melanomas as
to the role of MGMT, p53, and MMR proteins in the
O
6-alkylguanine-triggered killing response. Here, we investigated
the mode of cell death induced by TMZ and fotemustine in a panel
of human cutaneous malignant melanoma cell lines. Notably, we
assessed the question of cell death pathways (apoptosis, necrosis)
evoked by these drugs in melanomas. We provide, for the first
time, evidence that TMZ is a potent inducer of apoptosis in
melanoma cells. We also show that fotemustine has the ability to
induce both apoptosis and necrosis at high level. We furthermore
demonstrate the formation of DSBs (gH2AX) and caspase
activation, and elucidated the impact of MGMT, MMR, and p53
status on the response.
MATERIAL AND METHODS
Cell culture and drug treatment
The cell lines D03, D05, D14, MeWo, MeWo Fote40, MZ7, and SK29
were grown in RPMI-1640 medium containing 10% fetal calf serum,
G361 was grown in McCoy’s 5A medium containing 10% fetal calf
serum, A375 and RPMI7951 were grown in DMEM containing 10%
fetal calf serum, and Malme 3M was grown in DMEM containing
20% fetal calf serum. All cell lines were grown at 7% CO2,3 7 1Ci n
medium containing 100Uml
 1 penicillin and 100mgml
 1 strepto-
mycin. SK29-MEL (Wolfel et al, 1995), MZ7-MEL cells (Lennerz
et al, 2005), D03-, D05-, and D14-MEL (Pavey et al, 2004; Stark and
Hayward, 2007), and A365, Malme 3M, G361, and RPMI7951
(Haapajarvi et al, 1999) cells were described previously. N-methyl-
N0-nitro-N-nitrosoguanidine (MNNG; Sigma, Munich, Germany)
stocks were prepared by dissolving the drug in dimethyl sulphoxide
(DMSO) and then diluting with sterile dH2O to a 10mM concentra-
tion. Temozolomide (Schering-Plough, Kenilworth, NJ, USA) stocks,
with 35mM end concentration, were prepared by dissolving the drug
in pure DMSO. The MNNG and TMZ stocks were filtered, aliquoted,
and then stored at  801C till use. Fotemustine (diethyl1-[3-
(2-chloroethyl)-3-nitrosoureido]ethylphosphate; Muphoran, Servier
Research International, Neuilly sur Seine, France) was prepared
fresh for each treatment in a concentration of 1mgml
 1 in one-third
of ethanol and two-thirds sterile distilled H2O. To deactivate the
MGMT protein, 10mM O
6-benzylguanine (O
6BG) was added to the
cells 1h before drug treatment.
Determination of apoptosis
Sub-G1 Non-adherent and trypsinised adherent cells were com-
bined, suspended in cold PBS, and fixed in ice-cold 70% ethanol for a
minimum of 30min. DNA in the cells was stained with propidium
iodide (PI; 16.5mgml
 1) in PBS after RNase (0.03mgml
 1)d i g e s t i o n .
For each sample 10000 cells were subjected to flow cytometric
analysis using an FACS Calibur (Becton Dickinson, Heidelberg,
Germany). The number of apoptotic cells was calculated using the
computer program WinMDI 2.8 (Joseph Trotter, http://facs.scripps.
edu/software.html).
Annexin V/PI This assay distinguishes between early apoptotic
cells and late apoptotic/necrotic cells, by using annexin V/PI
double staining of unfixed cells. Cells in the supernatant and
trypsinised cells were combined and suspended in 50ml binding
buffer (10mM HEPES (pH 7.4), 140mM NaCl, 2.5mM CaCl, 0.1%
BSA). Annexin V-FITC (2.5ml; BD Pharmingen, Heidelberg,
Germany) was added to each samples. After 15min incubation in
the dark, 430ml binding buffer and 1mgml
 1 PI per sample were
added. The flow cytometric analysis was carried out using an FACS
Calibur (Becton Dickinson). For each sample 10000 cells were
analysed. The evaluation of the cell populations was performed
using the computer program WinMDI 2.8 (Joseph Trotter).
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sPreparation of protein extracts
For preparing whole-cell extracts, cells were washed in ice-cold
PBS, harvested, and re-suspended in whole-cell extract buffer
(20mM Tris-HCl; pH 8.5, 1mM EDTA, 1mM b-mercaptoethanol, 5%
glycerol, 10mM DDT, 0.5mM PMSF, 1mM Na3VO4, proteinase
inhibitor Complete; Roche, Mannheim, Germany). After sonication
on ice (two times for 10 pulses) with a Branson sonifier (Cell
Disruptor B15), output control¼4, 40% Duty Cycle, the homo-
genates were centrifuged (10000g, 10min at 41C), and the clear
supernatants were stored at  801C.
For fractionated extracts, cells were washed in ice-cold PBS,
harvested, and re-suspended in fractionation buffer A (10mM
HEPES-KOH; pH 7.4, 0.1mM EDTA, 1mM EGTA, 250mM sucrose,
10mM DDT, 0.5mM PMSF, 1mM Na3VO4, proteinase inhibitor
Complete; Roche). Cell membranes were disrupted by freezing in
liquid nitrogen and thawing at 371C, four times (after thawing, the
cell suspension was vortexed for 5s). After centrifugation of the
homogenates (700g, 10min at 41C) to separate the nuclei in a pellet,
the supernatant, including the cytoplasmic fraction, was transferred
to a new reaction tube whereas the pellet was kept on ice. The
supernatant was cleared by centrifugation (10000g, 10min at 41C)
and the pure cytoplasmic fraction was stored at  801C. The pellet
containing the nuclei was re-suspended in whole-cell extract buffer
(20mM Tris-HCl; pH 8.5, 1mM EDTA, 1mM b-mercaptoethanol, 5%
glycerol, 10mM DDT, 0.5mM PMSF, 1mM Na3VO4, proteinase
inhibitor Complete; Roche) and sonicated on ice with a Branson
sonifier (Cell Disruptor B15), output control¼4, 40% Duty Cycle,
two times for 10 pulses, the homogenates were centrifuged (10000g,
10min at 41C) and the supernatant containing the nuclear proteins
was stored at  801C.
Protein concentration determination
Protein concentrations were determined using the Bradford
method (Bradford, 1976). Bradford reagent (200ml; 0.01% G240
brilliant blue (Saba), 5% ethanol, 10% H3PO4, 85% dH2O)
was added to 10ml of a 1:10 dilution of the protein extracts.
Following 15min incubation in the dark, the absorption was
measured by photometry at 595nm. The protein concentration was
determined using a calibration curve with BSA protein, taken in
parallel.
Western blot analysis
The method used here is based on the method by Renart et al
(1979). Samples of 25mg of protein extracts were separated on a 7.5
or 12% SDS-polyacrylamide gel. Separated protein were blotted
onto a nitrocellulose transfer membrane (Schleicher and Schuell,
Dassel, Germany) in a Bio-Rad blot cell for 3h at 300mA using
buffer consisting of 25mM Tris-HCl, 86mM glycine, and 20%
methanol. The membranes were blocked for 1h at room
temperature in 5% (wt/vol) milk powder in TBS (150mM HCl,
20mM Tris pH 7.6) containing 0.1% Tween 20 (TBS–Tween) and
incubated overnight at 41C with the primary antibody (1:200–
1:1000 dilution) in 5% (wt/vol) milk powder or BSA in TBS–
Tween. The membranes were washed three times for 10min in
TBS–Tween each, incubated for 1h with a horseradish-peroxidase-
coupled secondary antibody (dilution 1:4000) (Amersham
Biosciences AB, Munich, Germany) in TBS–Tween and washed
again three times for 10min in TBS–Tween. For developing the
membranes, a chemiluminescence detection system (Amersham
Biosciences AB) was used. Western blots were quantified by
densitometric scanning of the blots. The antibodies used were anti-
PARP1 and anti-Erk2 (Santa Cruz Biotechnology, Heidelberg,
Germany), anti-caspase-3 and anti-caspase-7 (Cell Signaling, New
England Biolabs, Frankfurt, Germany), and anti-gH2AX (Upstate,
Millipore, Schwalbach, Germany).
Determination of MGMT activity
The MGMT activity was determined as previously described
(Preuss et al, 1995). It was expressed as fmol of [
3H]-methyl
transferred from radioactively labelled DNA to protein per mg of
total cell extract protein.
Mismatch repair assays
The MMR activity was determined as previously described
(Christmann and Kaina, 2000). For gel retardation assays,
29-nucleotide oligomers with the general sequence 50-GGG
CTCGAGCTGCAGCTGCTAGTAGATCT-30 were annealed to oli-
gomers with the general sequence 50-GGGAGATCTACTAGNA
GCTGCAGCTCGAG-30 (n¼C or T) and labelled with [
32P]dATP
using polynucleotide kinase. After incubation with nuclear
proteins DNA–protein complexes were separated on polyacryla-
mide gels.
Statistics
Statistical analysis was performed using the computer-based
program GraphPad Prism. For comparing differences between
two populations the unpaired t-test was performed. For regression
fits, the linear equation and the exponential decrease equation was
used.
RESULTS
First, we studied the response of a well-known melanoma cell line,
MeWo, to the model SN1-methylating agent MNNG. (This agent
acts similar to TMZ and DTIC by inducing O
6MeG adducts in the
DNA.) As shown in Figure 1A, MNNG induces a time-dependent
reduction in the fraction of G1 cells, an accumulation of cells in G2,
and a dramatic increase in the level of apoptotic sub-G1 cells. This
was most obvious late, that is 72–144h, after treatment.
Quantification of the sub-G1 population shows that apoptosis
starts 2 days after MNNG treatment and increases with increasing
post-exposure time (Figure 1A, right panel). This also holds true
for TMZ that induced apoptosis 4 days after treatment (Figure 1B
for representative histograms and time response of apoptosis of
TMZ-treated MeWo cells). We should note that the dose of TMZ
applied in these experiments (50mM) was rather low, that is below
the maximal clinical dose level (optimal plasma peak level
B100mM). Pretreatment of MeWo cells with O
6BG did not lead
to amelioration of TMZ-induced apoptosis (Figure 1B, inset of
right panel). This is in line with the finding that MeWo cells do not
express detectable MGMT (Christmann et al, 2001).
Next, we investigated a panel of melanoma cell lines that
originated from cutaneous malignant melanomas. As depicted in
Figure 1C, all but one cell line included in this study (D05, G361,
A375, Malme 3M, D03, D14, MeWo, SK29, and RPMI7951)
underwent apoptosis upon TMZ treatment, as measured by sub-
G1. There were clear differences in the sensitivity of the cell lines,
with RPMI7951 the most sensitive and G361 the most resistant.
Similar experiments were performed with the chloroethylating
drug fotemustine. As shown in Figure 1D, all but one melanoma
cell line underwent apoptosis upon treatment, again with
remarkably different sensitivities. D03 cells were the most sensitive
and G361 cells were the most resistant. Interestingly, the onset of
apoptosis was earlier for fotemustine- than for TMZ-treated cells;
it was observed 24h after the beginning of fotemustine treatment
whereas for TMZ it was observed after 72–96h (Figure 1B and data
not shown). It is important to note that all experiments with these
cell lines were performed under O
6BG pretreatment conditions to
deplete residual MGMT activity.
The induction of apoptosis by TMZ and fotemustine in
melanoma cells was confirmed using annexin V/PI double staining
TMZ and fotemustine-induced apoptosis in melanoma cells
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sand flow cytometry analysis, which allows for simultaneous
quantification of apoptosis and necrosis/late apoptosis (Vermes
et al, 1995). Data shown in Figure 2A (representative density dot
blots) and Figure 2B (for quantification) revealed that 60–90% of
cell killing resulted from apoptosis. The D14 cell line displayed
nearly the same amount of apoptosis (annexin-V-positive cells)
and necrosis/late apoptosis (annexin-V- and PI-positive cells) both
after treatment with TMZ and fotemustine. Necrosis was induced
in the cell lines at a frequency between 10 and 40%.
Having shown that malignant melanoma cells are able to
undergo apoptosis in response to TMZ and fotemustine, we
studied the activation of caspases. We observed a clear activation
of the executing caspases-3 and -7 upon TMZ and fotemustine
treatment (Figure 2C for D14 cells and Figure 2D for SK29 cells).
We also observed PARP cleavage, a hallmark of alkylation-induced
apoptosis (Ochs and Kaina, 2000; Figure 2C and D). Overall, the
data substantiate that malignant melanoma cells are able to
undergo apoptosis after treatment with methylating and chloro-
ethylating agents.
A major determinant of alkylating drug resistance is MGMT.
Therefore, we determined the activity of this repair protein in the
cell lines used in this study. They did not express detectable
MGMT (D03, D14, SK29, MZ7, MeWo) or express MGMT at levels
ranging between 100 and 400fmolmg
 1 protein (Figure 3A). For
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Figure 1 Apoptotic response after treatment with methylating agents in melanoma cells determined by quantifying the sub-G1 population using flow
cytometry. (A, left panel) Time-dependent flow cytometry histograms after treatment of MeWo cells with 5mM MNNG, (A, right panel) time-dependent
determination of apoptotic response following treatment of MeWo cells with 5mM MNNG. (B, left panel) Time-dependent flow cytometry histograms after
treatment of MeWo cells with 50mM TMZ, (B, right panel) time-dependent determination of apoptotic response following treatment of MeWo cells with
50mM TMZ. (C) Frequency of apoptosis in nine melanoma cell lines after treatment with 50mM TMZ. Cells were pretreated with 10mM O
6BG.
(D) Apoptotic response in nine melanoma cell lines after treatment with 32mM fotemustine and 10mM O
6BG. The baseline apoptosis level for the cell lines
was as follows: D05, 5.3%; G361, 9.5%; A375, 2.5%; Malme 3M, 11.1%; D03, 15.5%; D14, 8.8%; MeWo, 6.7%; SK29, 5.2%; RPMI7951, 11.6%.
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scomparison, we included a MeWo-derived cell line MeWoF40 that
was generated by continuous fotemustine selection (Christmann
et al, 2001), which expressed MGMT at very high level
(1160fmolmg
 1 protein; Figure 3A). MeWoF40 cells are highly
resistant to TMZ. If MGMT was depleted by O
6BG, apoptosis was
induced at a high level, similar to MGMT-deficient MeWo cells
(Figure 3B, left panel). Similar data were obtained with the cell
lines D05, G361, A375, Malme 3M, and RPMI7951, all cell lines
were MGMT positive and were sensitised following depletion of
MGMT with O
6BG; in four of the five lines (except G361 which is
extremely resistant even under MGMT-depleted conditions) the
sensitisation was significant (Po0.05; Figure 3B, right panel). This
shows that O
6MeG is the major apoptotic trigger in melanoma cells
treated with TMZ.
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Figure 2 Quantification of the apoptotic and the necrotic/late apoptotic population by annexin V/PI double staining and western blot following TMZ and
fotemustine treatment. (A) Representative flow cytometry density plots of cells not exposed and exposed to 50mM TMZ or 32mM fotemustine after 144h
in the presence of O
6BG (10mM) in the melanoma cell lines D14 and SK29, (B) ratio between apoptosis and necrosis/late apoptosis in TMZ- or
fotemustine-treated cells after 144h treatment in eight cell lines. For Malme 3M the TMZ time point was 196h. (C, D) Western blot analysis of effector
caspase-3 activation documented by the cleavage products p17 and p19, effector caspase-7 activation documented by cleavage product p20 and cleavageo f
PARP-1 protein (c-PARP-1) following treatment with 100mM TMZ and O
6BG (10mM), or 32mM fotemustine and O
6BG (10mM) in two representative
melanoma cell lines D14 (C) and SK29 (D).
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sMeWoF40 cells are also highly resistant to fotemustine. Under
MGMT-depleted conditions, the cells approached the sensitivity of
MeWo cells not expressing MGMT (Figure 3C, left panel)
indicating that O
6-chloroethylguanine, which is subject to repair
by MGMT, is responsible for fotemustine-induced apoptosis in
melanoma cells. This was confirmed with D05, G361, A375, Malme
3M, and RPMI7951 cells when MGMT was inactivated by O
6BG
(Figure 3C, right panel). All cell lines but one (G361, which
was completely refractory to apoptosis) showed an increased
sensitivity to fotemustine when MGMT was inhibited. To further
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Figure 3 Determination of the influence of MGMT on alkylation at position O
6 of guanine by treatment with TMZ and fotemustine. (A) Determination of
MGMT activity (fmolmg
 1 protein) in 11 melanoma cell lines. Time dependence of the apoptotic response as determined by quantifying the sub-G1
population by flow cytometry after treatment with 50mM TMZ with or without co-treatment with 10mM O
6BG in MeWoF40 cells (B, left panel). Apoptotic
response of D05, G361, A375, Malme 3M, and RPMI7951 cells to 50mM TMZ with or without co-treatment with O
6BG 144h later. For D05, A375, Malme
3M, and RPMI7951 the sensitisation was significant (Po0.05) (B, right panel). Time dependence of the apoptotic response as determined by quantifying the
sub-G1 population by flow cytometry after treatment with 32mM fotemustine with or without co-treatment with 10mM O
6BG in MeWoF40 cells (C, left
panel). Apoptotic response of D05, G361, A375, Malme 3M, and RPMI7951 cells to 32mM fotemustine with or without co-treatment with O
6BG 144h later.
For D05 and RPMI7951 the sensitisation was significant (Po0.05) (C, right panel). (D) Frequency of apoptosis as determined by quantifying the sub-G1
population by flow cytometry after treatment with TMZ and fotemustine for 120h in non-transfected and MGMT transient transfected SK29 cells
(*decrease of apoptotic response in MGMT transfected cells in comparison to control is significant, Po0.01). Expression of MGMT protein was determined
by western blot analysis in non-transfected (lane 1) and MGMT transient transfected SK29 cells (lane 2) at the time of drug treatment. (E) Induced level of
apoptosis after TMZ (50mM) or fotemustine treatment (32mM) as a function of MGMT activity level. Data points were fitted to a line depicting an
exponential decrease with plateau at 0% induced apoptosis. The correlation is significant.
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sshow the protective effect of MGMT, SK29 cells were transiently
transfected with MGMT cDNA. The data show that ectopic over-
expression of MGMT significantly reduced apoptosis both after
treatment with TMZ and fotemustine (Figure 3D). Further, we
compared the apoptotic response with the MGMT level expressed
in the cell lines utilised in the study. There was a significant
correlation between the MGMT activity level and the degree of
resistance to TMZ- and fotemustine-induced apoptosis
(Figure 3E). This shows that in melanoma cell lines MGMT is a
decisive marker of alkylating drug resistance.
Comparing the apoptotic response of different melanoma cell
lines, one cell line (designated MZ7) was highly resistant to TMZ
and did not undergo apoptosis (Figure 4A, left panel for a time-
course experiment), although these cells did not express MGMT
(Figure 3A). As expected, O
6BG did not affect the response of these
cells to TMZ (Figure 4A). When MZ7 cells were treated with
fotemustine, they underwent apoptosis at a high level and O
6BG
slightly sensitised the cells (Figure 4A). Obviously, MZ7 cells have
the ability to undergo apoptosis after exposure to fotemustine, but
not TMZ. O
6-MeG-triggered apoptosis requires DNA MMR, which
is not essential for apoptosis induced by chloroethylating drugs
(Liu et al, 1996; Pepponi et al, 2003). Therefore, we speculated that
MZ7 cells are impaired in MMR. Indeed, the level of MutSa
binding to a G/T mismatch-containing oligonucleotide was clearly
different in MZ7 cells compared to the other melanoma cell lines
studied, showing a protein–DNA complex with a lower molecular
weight (Figure 4B). Thus, it appears that in MZ7 cells MMR is
impaired, causing them to be highly resistant to TMZ. MutSa is
composed of MSH2 and MSH6, the expression of which is shown
in Figure 4C. MZ7 cells express a very low amount of MSH2 and
MSH6 (at the border level of detection), which supports the
inference that these cells are MMR impaired. The expression level
of MSH2 and MSH6 in the other lines is higher than in MZ7 cells
and quite variable. Importantly, comparing the response of the
different cell lines, there was no correlation between MSH2 and
MSH6 expression level and the sensitivity to TMZ (Figure 4D).
On the basis of data obtained with repair-defective mutants, it
was proposed that O
6MeG lesions are converted by means of MMR
and DNA replication into DSBs that act as a final trigger of
apoptosis (Ochs and Kaina, 2000). Therefore, we were interested in
determining the level of DSBs in response to TMZ and fotemustine
in different melanoma cell lines. As an indicator of DSBs we
measured the total amount of phosphorylation of histone
H2AX, which occurs in response to DSBs (Rogakou et al, 1998).
As shown in Figure 5A, gH2AX was induced at different levels in
the melanoma cell lines (Erk2 served as loading control). The
highest level of induction was seen in D14, D03, and SK29 cells, the
lowest level in MeWo, D05, and MZ7. Comparing the gH2AX
induction level with the apoptotic response, a significant correla-
tion was found between both end points (Figure 5B), which
supports the hypothesis that DSBs are involved in TMZ-induced
cell death.
A similar study was performed for fotemustine. Figure 5C
outlines the time course of gH2AX induction. Unlike TMZ (data
not shown), fotemustine induced gH2AX already after 24h, which
is shown for the most sensitive lines D03, D14, and SK29. Overall,
high level of gH2AX induction was found in D03, D14, and SK29
cells, and low level of induction in MeWo, D05, and MZ7.
Interestingly, the level of gH2AX induction did not correlate at any
of the time points (24, 48, and 120h) with the level of fotemustine-
induced apoptosis (Figure 5D). Thus, it appears that fotemustine-
induced cell killing is based on a more complex mechanism in
which DSBs may only be one of the several downstream
components.
In previous studies we showed that p53 determines the
sensitivity of glioma cells to TMZ and ACNU (Batista et al, 2007;
Roos et al, 2007a). Therefore, we hypothesised that p53 may also
be involved in alkylating drug resistance in melanoma cells. D05
cells are wild type for p53 (Packer et al, 2007); it becomes stabilised
upon treatment with TMZ (Figure 6A) and fotemustine
(Figure 6B), which is in line with DSBs formed in response to
the treatments. Stabilisation of p53 provoked up-regulation of
p21 as observed 48 and 72h after TMZ and fotemustine treatment
(Figure 6C), which indicates that p53 is functional. Transfection of
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Figure 4 Influence of MMR on apoptotic response following TMZ or
fotemustine treatment in the MMR-impaired cell line MZ7. (A) Time
dependence of the apoptotic response as determined by quantifying the
sub-G1 population by flow cytometry after treatment with 50mM TMZ or
32mM fotemustine with or without co-treatment with 10mM O
6BG.
(B) Measurement of the G/T binding activity of the MutSa complex in
seven melanoma cell lines using the mismatch repair assay, (C) level of
expression of MSH2 and MSH6 protein in different melanoma cell lines;
Erk2 was used as loading control. (D) Induced level of apoptosis after TMZ
treatment (50mM) as a function of MSH2 and MSH6 expression level
(relative to D03 that was set to 1). The correlation is not significant.
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sp53 siRNA nearly completely abolished basal p53 expression
and prevented TMZ- and fotemustine-induced p53 up-regulation
as well as p53 (Ser15) phosphorylation (Figure 6A and B).
However, down-regulation of p53 by siRNA transfection did not
impact the level of apoptosis after TMZ treatment (Figure 6A, right
panel), indicating p53 does not stimulate TMZ-induced cell death.
It slightly enhanced the level of apoptosis after fotemustine
(Figure 6B, right panel), which is in line with a protective role of
p53 for chloroethylating agents by stimulation of DNA repair
(Batista et al, 2007).
If p53 does not stimulate TMZ-induced apoptosis in melanoma
cells one would expect p53 wild-type melanoma cells not to be
more sensitive than p53 mutant cells. This appears to be the case:
in Figure 6D we compared p53 wild-type and p53 mutant
melanoma cells. The comparison revealed that the cells expressing
p53 wild type are, on average, more resistant to TMZ than p53-
mutated cells (Figure 6D, left panel). p53 wild-type cells were also
more resistant to fotemustine than lines expressing mutant p53
(right panel). As discussed below, the TMZ response is in marked
contrast to the response of glioma cells.
DISCUSSION
First-line therapy of metastatic melanoma relies on the methylat-
ing and chloroethylating anticancer drugs DTIC, TMZ (Temodal),
BCNU (Carmustine), and fotemustine (Muphoran). The mechan-
ism of action of these agents at the DNA level has been well
described. Temozolomide and DTIC methylate DNA at 13 sites
(Kaina et al, 2007). One of the methylation products is O
6MeG that,
upon mispairing with thymine, activates MutSa-dependent MMR
that triggers apoptosis (Kaina et al, 1997; Tominaga et al, 1997;
Meikrantz et al, 1998). Fotemustine and other chloroethylating
nitrosoureas induce O
6-chloroethylguanine, which gives rise to
N1-guanine-N3-cytosine crosslinks by inter- and intra-molecular
rearrangement B8h after induction of the primary lesion
(Brent et al, 1987). The molecular cell death pathways triggered
by the critical DNA lesions are not predictable and appear
to be dependent on the cellular background. Thus, the same
DNA lesion can induce apoptosis, necrosis, or cellular senescence
and growth arrest (Roos and Kaina, 2006), the reason for which is
often unclear. For TMZ, there is evidence that DSBs are involved as
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Figure 5 Phosphorylation status of H2AX in six melanoma cell lines. (A) Expression level of gH2AX protein after treatment with 100mM TMZ and O
6BG
(10mM) for 120h, (B) significant correlation (P¼0.035) between induced H2AX phosphorylation and induced apoptotic response as determined by
quantifying the sub-G1 population by flow cytometry 120h after TMZ treatment (50mM). (C) Western blot analysis of gH2AX after treatment with 32mM
fotemustine and O
6BG (10mM) for 24, 48, and120h, (D) not significant correlation between induced gH2AX phosphorylation for 24h (left panel,
P¼0.354), 48h (middle panel, P¼0.154), and 120h (right panel, P¼0.885) and induced apoptotic response as determined by flow cytometry 120h after
fotemustine treatment.
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sa downstream trigger of apoptosis (Roos et al, 2009), which
is yet unknown for fotemustine. It has also been shown that p53
has a critical dual function. In gliomas, p53 wild-type cells
are more sensitive to TMZ, but more resistant to ACNU than
p53 mutant cells, which was explained by up-regulation of CD95
death receptor or DNA repair (Batista et al, 2007; Roos et al,
2007a).
In this study, we elucidated the mechanism of death of
malignant melanoma cells upon treatment with TMZ or fotemus-
tine. We show that melanoma cells treated with the agents die by
apoptosis and necrosis, with apoptosis being the major death
pathway. Apoptosis was accompanied by caspase-7 and -3
activation and PARP cleavage. This is in contrast to a recent
report stating that TMZ induces senescence, but not apoptosis in
melanoma cells (Mhaidat et al, 2007). The failure to observe
apoptosis in that study might be explained by the different post-
exposure times that were used. Thus, in the study by Mhaidat et al
(2007) the expression of apoptosis marker such as caspase-3 and
the cleaved PARP fragment was analysed 24–72h after TMZ
treatment. This seems to be a too short time period for apoptosis
activation because TMZ-induced apoptosis is a late response that
needs the passage of cells through at least two cell cycles after
treatment (Kaina et al, 2007). Taking into account additional cell-
cycle inhibition due to high-dose treatment, apoptosis in some cell
types such as gliomas will only be visible 4–6 days after treatment
(Roos et al, 2007a). Using time-course experiments we found that
melanoma cells start undergoing apoptosis 72h after the addition
of TMZ to the medium. Interestingly, fotemustine induced
apoptosis at earlier times, starting 24h after treatment. This is to
be expected because the toxic effect of chloroethylating agents does
not rely on MMR (Liu et al, 1996; Pepponi et al, 2003) and,
therefore, cytotoxicity is exerted earlier, likely in the treatment cell
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Figure 6 Activation of p53 and down-regulation by p53 siRNA. (A) D05 melanoma cells pretreated with O
6BG (10mM) were treated with TMZ (50mM)
and (B) fotemustine (32mM) and cells were harvested 72h later. Control and p53 siRNA was transfected 24h before the treatment with the drugs
occurred. p53, p53 (Ser15 phosphorylated), and p21 were determined by western blots, and apoptosis (right panels) was quantified by sub-G1. Data are the
mean of four independent experiments ±s.d. (C) Western blot analysis of the expression of p21 following treatment of cells with 50mM TMZ or 32mM
fotemustine. ERK2 was used as loading control. (D) Apoptosis induced in melanoma cells that are wild type or mutated for p53 144h following TMZ
(50mM) (left panel) or fotemustine (32mM) (right panel). Data for the cell lines D05, G361, A375, Malme 3M, D14, MeWo, and RPMI7951 for which the p53
status is known were taken from Figure 1C and D.
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scycle. This has been recently shown for the cyclophosphamide
analogue mafosfamide that induces, similar to fotemustine, ICLs
that trigger apoptosis in S and G2 phases of the treatment cell cycle
(Goldstein et al, 2008).
For TMZ, we show that gH2AX is induced before apoptosis,
which is indicative of the formation of DSBs. The frequency of
DSBs was quantitatively correlated with the frequency of
apoptosis. This supports a model where MMR generates gaps in
the DNA (Mojas et al, 2007) that block replication, which leads to
DSBs at collapsed replication forks in the second cell cycle after
treatment (Ochs and Kaina, 2000; for review see Kaina et al, 2007).
Thus, DSBs are postulated to act as a downstream trigger of
O
6MeG-induced apoptosis. The quantitative correlation between
gH2AX and sensitivity of melanoma cells to TMZ supports this
notion and suggests that gH2AX might be a useful predictive
indicator for the melanoma response to a methylating-agent-based
therapy. Interestingly, for fotemustine, a correlation between DSBs
and the apoptotic response was not found, which indicates that for
chloroethylating agents DSBs are not (or not the only) downstream
apoptosis-triggering lesion. Contrary to O
6MeG, ICLs prevent
genes from being transcribed and, therefore, transcriptional
inhibition could be involved. This conforms to previous findings
with crosslinking agents for which transcriptional inhibition was
shown to activate apoptosis (Ljungman et al, 1999; Arima et al,
2005; Goldstein et al, 2008). The question whether transcriptional
inhibition has the main function in apoptosis triggered by
therapeutic doses of fotemustine in melanoma cells is currently
under study.
The cell death response of the melanoma lines was dependent on
the MGMT level, which was shown by (1) the existence of an
inverse correlation between the MGMT activity and TMZ-induced
apoptosis, (2) inhibition of MGMT by O
6-benzylguanine that
sensitised all MGMT-expressing melanoma lines, and (3) transfec-
tion with MGMT which caused TMZ apoptotic resistance. The
data are in line with other reports showing that MGMT protects in
vitro against TMZ-induced melanoma cell death (Pepponi et al,
2003; Pagani et al, 2007). They are in line with the view that O
6MeG
and O
6-chloroethylguanine are the most critical primary DNA
lesions induced by TMZ and fotemustine in melanoma cells. Two
cell lines (out of 11) were identified that exhibited a highly
resistant phenotype. Band-shift experiments with extracts of one of
these lines (MZ7) revealed an abnormal complex bound to a G/T
oligonucleotide. Also, the expression of MSH2 was very low and
MSH6 was not detectable indicating that this melanoma cell line is
MMR defective. We should note that this line was generated from a
malignant melanoma patient following treatment with DTIC.
Therefore, the observed alteration in MMR might have occurred
during therapy and might be an impressive example of acquired
DTIC resistance. The extremely high level of resistance of another
cell line, G361, to both TMZ and fotemustine is striking. It
presumably relies on a downstream apoptosis execution defect,
which is currently under study.
Abnormal levels of MMR proteins were reported in metastatic
melanomas (Lage et al, 1999; Lo Muzio et al, 2000; Ma et al, 2002b;
Shpitz et al, 2005). Because of this, and the high frequency of
MMR-defective melanoma cell line (1 out of 11), down-regulation
or impaired MMR might be considered (together with up-
regulation of MGMT) a cause of acquired resistance to TMZ and
other methylating drugs. This, however, does not explain the
resistance of melanoma cells to fotemustine, with a low response
rate similar to TMZ of B20% (Li and McClay, 2002). Therefore, it
is possible that downstream defects, notably in the signalling and
execution of apoptosis, are majorly responsible for melanoma drug
resistance.
We also demonstrate activation of p53 upon TMZ and
fotemustine treatment in melanoma cells. The apoptotic response
of melanoma cells to TMZ was not related, however, to the p53
wild-type status. Thus, the cell lines expressing p53 wild type were,
on average, more resistant to TMZ than p53 mutant cell lines
(Figure 6D). Also, down-regulation of p53 by siRNA did not
impact on TMZ sensitivity. This is in marked contrast to glioma
cells that respond to methylating agents clearly better if p53 was
wild type and worse if p53 was mutated or down-regulated (Roos
et al, 2007a). For chloroethylating agents we found p53 wild-type
melanoma cells again more resistant than p53 mutant cells
(Figure 6D), which is in line with previous data obtained with
glioma cells (Batista et al, 2007). Therefore, it appears that the role
of p53 in the regulation of apoptosis upon TMZ treatment is
different in melanoma cells than in gliomas and presumably other
cancer cells. Whether and how this is related to the drug-resistant
phenotype of melanoma cells is currently under study.
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